Weikang Bio-Technology Group (fka WKBT)

[Rayhuh]

01/12/2011 Weikang engages RedChip

12.01.2011 16:29
Weikang Bio-Technology Engages RedChip Companies to Lead Public and Investor Relations Efforts

HARBIN, China, Jan. 12, 2011 /PRNewswire-Asia-FirstCall/ -- Weikang Bio-Technology Group Co., Inc. (BULLETIN BOARD: WKBT) ("Weikang" or the "Company"), a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nutritional products in the People's Republic of China, today announced that it has engaged RedChip Companies, Inc., to lead its public and investor relations efforts.

Yin Wang, Chairman and CEO of Weikang, stated, "We selected RedChip based on their proven track record of increasing investor awareness for emerging growth companies, as well as their international presence and innovative multimedia platform of products and services. We are confident that RedChip will help us attract new investors while strengthening our relationships with current shareholders."

"We are pleased to have the opportunity to represent Weikang," said Dave Gentry, President of RedChip Companies, Inc. "China is expected to become the world's third-largest pharmaceutical market by 2020, with market growth driven by national healthcare reform initiatives and a rapidly aging population. Weikang has an impressive portfolio of high-margin pharmaceutical and nutritional products and has achieved strong revenue and net income growth in recent years. We look forward to implementing a comprehensive investor and media relations program and introducing them to our investor network."

About Weikang Bio-Technology Group Co., Inc.

Weikang Bio-Technology Group Co., Inc. is principally engaged in developing, manufacturing and distributing Traditional Chinese Medicine (TCM), and health and nutritional supplements in China, in compliance with requisite Chinese licenses and approvals. The Company is also expanding its business scope to develop, manufacture and distribute Chinese herbal extract products and GMP-certified western prescription and OTC pharmaceuticals through its acquisition of Tianfang Pharmaceutical Co., Ltd. For more information, please visit http://www.weikangbio.com/.